ASRT - デポメッド (Assertio Therapeutics Inc.) デポメッド

 ASRTのチャート


 ASRTの企業情報

symbol ASRT
会社名 Assertio Therapeutics Inc (デポメッド)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 デポメッド(Depomed Inc)専門製薬会社である。同社は疼痛および他の中枢神経系(CNS)疾患を主要治療対象とする。同社の製品はNUCYNTA ER(タペンタドール延長放出錠剤)、NUCYNTA IR (NUCYNTA)(タペンタドール)、Gralise(ガバペンチン)、CAMBIA(経口溶液用ジクロフェナクカリウム)、Zipsor(ジクロフェナクカリウム)、及びLazanda(フェンタニル)を含む。同社のNUCYNTA ER(タペンタドール延長放出錠剤)は成人における糖尿病性末梢神経障害に関連する神経因性疼痛を含む毎日の長期オピオイド治療が必要な疼痛管理製品で、NUCYNTA IR(タペンタドール)は大人の重度の急性痛に対する製品である。同社のGralise(ガバペンチン)はヘルペス後神経痛の1日1回製品である。CAMBIA(経口溶液用ジクロフェナクカリウム)は片頭痛発作の急性の治療のための製品である。   デポメッドは、痛みや中枢神経系疾患に焦点を当てた米国の製薬会社。主要薬品は、帯状疱疹後神経痛薬Gralise(ガバペンチン)急性の痛みを軽減する液体充填カプセルZipsor(ジクロフェナクカリウム)、成人のがん患者向け痛み止め薬鼻スプレ―Lazanda(フェンタニル)、偏頭痛薬CAMBIA(ジクロフェナクカリウム経口溶液)などを含む。   Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.
本社所在地 7999 Gateway Boulevard Suite 300 Newark CA 94560 USA
代表者氏名
代表者役職名
電話番号 +1 224-419-7106
設立年月日 34912
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 434人
url www.depomed.com
nasdaq_url https://www.nasdaq.com/symbol/asrt
adr_tso
EBITDA EBITDA(百万ドル) 171.81900
終値(lastsale) 5.79
時価総額(marketcap) 370072285.14
時価総額 時価総額(百万ドル) 361.76320
売上高 売上高(百万ドル) 381.49800
企業価値(EV) 企業価値(EV)(百万ドル) 884.56820
当期純利益 当期純利益(百万ドル) -10.82000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Assertio Therapeutics Inc revenues increased less than 1% to $191.7M. Net income totaled $12.8M vs. loss of $53.4M. Revenues reflect Royalties and milestones increase from $387K to $5.5M also reflect Product Sales decrease of 63% to $71.2M. Net income reflects Selling general and administrative expe decrease of 40% to $55.5M (expense).

 ASRTのテクニカル分析


 ASRTのニュース

   World Neuropathy Pain Treatment Market Analysis 2020, Featuring Key Players Assertio Therapeutics Inc., Endo International Plc and Pfizer - ResearchAndMarkets.com  2020/05/21 12:04:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Global Neuropathy Pain Treatment Market 2020-2024" report has been added to ResearchAndMarkets.com's offering. The neuropathy pain treatment market is poised to grow by $ 1702.89 mn during 2020-2024 progressing at a CAGR of 5% during the forecast period. The report on the neuropathy pain treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The market i
   Assertio Therapeutics Announces Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes Due 2021 and 5.00% Senior Convertible Notes Due 2024 | MarketScreener  2020/03/11 05:02:04 MarketScreener
LAKE FOREST, Ill., March 11, 2020 -- Assertio Therapeutics, Inc. , today announces that it has commenced cash tender offers to purchase any and all of the outstanding $42,465,000 in… | March 11, 2020
   Is ASSERTIO THERAPEUTICS, INC (ASRT) Outperforming Other Medical Stocks This Year?  2020/01/22 16:30:09 Zacks Investment Research
Is (ASRT) Outperforming Other Medical Stocks This Year?
   Assertio Therapeutics Announces Closing of Gralise® Sale to Alvogen and Expects Full-Year 2019 Neurology Franchise Net Sales Above Upper End of Prior Guidance | MarketScreener  2020/01/13 12:51:02 MarketScreener
LAKE FOREST, Ill., Jan. 13, 2020 -- Assertio Therapeutics, Inc. , today announced the closing of its previously disclosed agreement with Alvogen, a global privately held pharmaceutical… | January 13, 2020
   The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares  2019/12/10 12:56:02 Benzinga
The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Aptose Biosciences Inc (NASDAQ: APTO ) (moved on ASH presentation) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL ), which agreed to be bought by Merck & Co., Inc. (NYSE: MRK ) Arvinas Inc (NASDAQ: ARVN ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BioNTech SE – ADR (NASDAQ: BNTX ) BridgeBio Pharma Inc (NASDAQ: BBIO ) (appointed oncology scientist Eli Wallace as chief scientific officer for its oncology programs) Bristol-Myers Squibb Co (NYSE: BMY ) (reacted to ASH presentation) Constellation Pharmaceuticals Inc (NASDAQ: CNST ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Epizyme Inc (NASDAQ: EPZM ) (reacted to ASH presentation) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) (reacted to ASH presentation) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Globus Medical Inc (NYSE: GMED ) Immunomedics, Inc.
   World Neuropathy Pain Treatment Market Analysis 2020, Featuring Key Players Assertio Therapeutics Inc., Endo International Plc and Pfizer - ResearchAndMarkets.com  2020/05/21 12:04:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Global Neuropathy Pain Treatment Market 2020-2024" report has been added to ResearchAndMarkets.com's offering. The neuropathy pain treatment market is poised to grow by $ 1702.89 mn during 2020-2024 progressing at a CAGR of 5% during the forecast period. The report on the neuropathy pain treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The market i
   Assertio Therapeutics Announces Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes Due 2021 and 5.00% Senior Convertible Notes Due 2024 | MarketScreener  2020/03/11 05:02:04 MarketScreener
LAKE FOREST, Ill., March 11, 2020 -- Assertio Therapeutics, Inc. , today announces that it has commenced cash tender offers to purchase any and all of the outstanding $42,465,000 in… | March 11, 2020
   Is ASSERTIO THERAPEUTICS, INC (ASRT) Outperforming Other Medical Stocks This Year?  2020/01/22 16:30:09 Zacks Investment Research
Is (ASRT) Outperforming Other Medical Stocks This Year?
   Assertio Therapeutics Announces Closing of Gralise® Sale to Alvogen and Expects Full-Year 2019 Neurology Franchise Net Sales Above Upper End of Prior Guidance | MarketScreener  2020/01/13 12:51:02 MarketScreener
LAKE FOREST, Ill., Jan. 13, 2020 -- Assertio Therapeutics, Inc. , today announced the closing of its previously disclosed agreement with Alvogen, a global privately held pharmaceutical… | January 13, 2020
   The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares  2019/12/10 12:56:02 Benzinga
The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Aptose Biosciences Inc (NASDAQ: APTO ) (moved on ASH presentation) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL ), which agreed to be bought by Merck & Co., Inc. (NYSE: MRK ) Arvinas Inc (NASDAQ: ARVN ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BioNTech SE – ADR (NASDAQ: BNTX ) BridgeBio Pharma Inc (NASDAQ: BBIO ) (appointed oncology scientist Eli Wallace as chief scientific officer for its oncology programs) Bristol-Myers Squibb Co (NYSE: BMY ) (reacted to ASH presentation) Constellation Pharmaceuticals Inc (NASDAQ: CNST ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Epizyme Inc (NASDAQ: EPZM ) (reacted to ASH presentation) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) (reacted to ASH presentation) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Globus Medical Inc (NYSE: GMED ) Immunomedics, Inc.
   Assertio Therapeutics Announces Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes Due 2021 and 5.00% Senior Convertible Notes Due 2024 | MarketScreener  2020/03/11 05:02:04 MarketScreener
LAKE FOREST, Ill., March 11, 2020 -- Assertio Therapeutics, Inc. , today announces that it has commenced cash tender offers to purchase any and all of the outstanding $42,465,000 in… | March 11, 2020
   Is ASSERTIO THERAPEUTICS, INC (ASRT) Outperforming Other Medical Stocks This Year?  2020/01/22 16:30:09 Zacks Investment Research
Is (ASRT) Outperforming Other Medical Stocks This Year?
   Assertio Therapeutics Announces Closing of Gralise® Sale to Alvogen and Expects Full-Year 2019 Neurology Franchise Net Sales Above Upper End of Prior Guidance | MarketScreener  2020/01/13 12:51:02 MarketScreener
LAKE FOREST, Ill., Jan. 13, 2020 -- Assertio Therapeutics, Inc. , today announced the closing of its previously disclosed agreement with Alvogen, a global privately held pharmaceutical… | January 13, 2020
   The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares  2019/12/10 12:56:02 Benzinga
The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Aptose Biosciences Inc (NASDAQ: APTO ) (moved on ASH presentation) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL ), which agreed to be bought by Merck & Co., Inc. (NYSE: MRK ) Arvinas Inc (NASDAQ: ARVN ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BioNTech SE – ADR (NASDAQ: BNTX ) BridgeBio Pharma Inc (NASDAQ: BBIO ) (appointed oncology scientist Eli Wallace as chief scientific officer for its oncology programs) Bristol-Myers Squibb Co (NYSE: BMY ) (reacted to ASH presentation) Constellation Pharmaceuticals Inc (NASDAQ: CNST ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Epizyme Inc (NASDAQ: EPZM ) (reacted to ASH presentation) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) (reacted to ASH presentation) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Globus Medical Inc (NYSE: GMED ) Immunomedics, Inc.
   The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend  2019/12/06 12:39:38 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 5) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD )(presented positive Phase 3 data for pimavanserin in dementia-related psychosis) Allergan plc (NYSE: AGN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Applied Therapeutics Inc (NASDAQ: APLT ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH )( reported positive readout for a pivotal trial in volcosporin for lupus nephritis) Bristol-Myers Squibb Co (NYSE: BMY ) Cassava Sciences Inc (NASDAQ: SAVA ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Incyte Corporation (NASDAQ: INCY ) Merck & Co., Inc. (NYSE: MRK ) Morphosys Ag (NASDAQ: MOR ) NuVasive, Inc. (NASDAQ: NUVA ) Oyster Point Pharma Inc (NASDAQ: OYST ) PTC Therapeutics, Inc.

 関連キーワード  (医薬品 米国株 デポメッド ASRT Assertio Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)